Main Content

Top Content

Self-Assessment Post-Test

Self-Assessment Post-Test

RIUPost-Test(Cytogen)_04-12.qxd 12/4/06 13:12 Page S39 SELF-ASSESSMENT POST-TEST The Evolving Role of Imaging in Identification and Management of Prostate Cancer There are no fees for participating and receiving CME credit for this activity. During the period April 2006 through April 30, 2007, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-test by recording the best answer to each question in the answer key on the evaluation form; 4) complete the evaluation form; and 5) mail or fax the evaluation form with answer key to Postgraduate Institute for Medicine. A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be mailed to you within 4 weeks. 1. Which of the following is the least accurate indicator of the extent of prostate cancer disease? a. prostate-specific antigen (PSA) b. clinical nomograms c. prediction of lymph node metastasis d. magnetic resonance imaging (MRI) with contrast 2. Prostate-specific membrane antigen (PSMA) is expressed in which of the following? a. higher-grade lesions b. androgen-insensitive tissue c. metastatic deposits d. all of the above 3. 4. 5. Patients with prostate cancer that overexpresses PSMA: a. are at no additional risk for recurrence compared to those who have normal PSMA expression b. have twice the recurrence rate as those with normal PSMA expression c. are at risk for a shorter time to tumor recurrence than those with normal PSMA expression d. b and c Fused ProstaScint® and MRI images provide valuable data for which of these purposes? a. to guide focal brachytherapy based on increased signal in particular areas b. to predict better outcomes on the basis of the absence of distant signal intensity c. to direct increased dosimetry to focal areas of increased uptake within the gland d. all of the above Limitations of conventional ultrasound imaging (gray scale harmonic imaging) include: a. the ease of confusion between prostatitis and benign hyperplasia with prostate cancer b. the high cost and difficulty obtaining third-party payment approval c. the fact that half of prostate cancer lesions are invisible by gray scale imaging d. a and b 6. Advantages of conventional ultrasound imaging over color and Doppler images include: a. no blooming of the harmonic gray scale enhancement around a vessel b. superior spatial and temporal resolution allows better visualization c. avoids the color flash artifacts that interfere with needle placement d. all of the above 7. Which of the following are true of endoMRI/MRSI imaging? a. MRI/MRSI adds the greatest value in intermediate and high-risk groups b. Cancers less than 0.1 cm in diameter are easily visualized using MRI/MRSI c. The cancer grade has no effect on the ability of MRI/MRSI to detect tumors d. MRI/MRSI evaluation of the prostate gland should be performed immediately after needle biopsy 8. The use of dose escalation to discrete tumor targets identified by radioimmunoscintigraphy: a. benefits biochemical disease-free survival b. reduces radiotherapy-related morbidity for prostate cancer c. a and b 9. Capromab pendetide imaging is most commonly used: a. to delineate local from metastatic disease b. to add clarity when there is discordance among the PSA, Gleason score, and prostate examination c. to evaluate post-prostatectomy patients for whom radiotherapy is being considered d. all of the above 10. True or false? Fused capromab pendetide imaging with newer SPECT processing techniques improve the accuracy and precision of indium-111-based molecular images. a. true b. false EVALUATION FORM The Evolving Role of Imaging in Identification and Management of Prostate Cancer Project ID: 3680 ES 13 Postgraduate Institute for Medicine respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form. You must complete this evaluation form to receive acknowledgment of participation for this activity. VOL. 8 SUPPL. 1 2006 REVIEWS IN UROLOGY S39 RIUPost-Test(Cytogen)_04-12.qxd 12/4/06 13:12 Page S40 Please answer the following questions by circling the appropriate rating: 5  Outstanding 4  Good 3  Satisfactory 2  Fair 1  Poor EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED OBJECTIVES After completing this activity, participants should be better able to: • Describe the role of imaging in diagnosing and treating prostate cancer • Identify applications of imaging in diagnosing and treating patients, including high-risk patients • Discuss the use of molecular imaging agents for diagnosing cancer of the prostate • Describe the use of molecular imaging agents for the treatment of prostate cancer in high-risk patients • Describe the value of co-registration (image fusion) in the diagnosis and treatment of prostate cancer 5 5 5 5 5 4 4 4 4 4 3 3 3 3 3 2 2 2 2 2 1 1 1 1 1 5 5 5 5 4 4 4 4 3 3 3 3 2 2 2 2 1 1 1 1 OVERALL EFFECTIVENESS OF THE ACTIVITY • • • • Was timely and will influence how I practice Will assist me in improving patient care Fulfilled my educational needs Avoided commercial bias or influence IMPACT OF THE ACTIVITY The information presented: (check all that apply) ❒ Reinforced my current practice/treatment habits. ❒ Provided new ideas or information I expect to use. ❒ Will improve my practice/patient outcomes. ❒ Enhanced my current knowledge base. ❒ Yes Will the information presented cause you to make any changes in your practice? ❒ No If yes, please describe any change(s) you plan to make in your practice as a result of this conference: How committed are you to making these changes? (Very committed) 5 4 3 2 1 (Not at all committed) FUTURE ACTIVITIES Do you feel future activities on this subject matter are necessary and/or important to your practice? ❒ Yes ❒ No Please list any other topics that would be of interest to you for future educational activities: FOLLOW-UP As part of our ongoing quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey: ❒ Yes, I would be interested in participating in a follow-up survey. ❒ No, I’m not interested in participating in a follow-up survey. Additional comments about this activity: POST-TEST ANSWER KEY If you wish to receive acknowledgment of participation for this activity, please complete the post-test by selecting the best answer to each question, complete this evaluation verification of participation, and fax to: (303) 790-4876. 1___ 2___ 3___ 4___ 5___ 6___ 7___ 8___ 9___ 10___ Request for Credit Name Degree Organization Address City, State, Zip Telephone Signature Specialty Fax E-Mail Date Completed FOR PHYSICIANS ONLY I certify my actual time spent to complete this educational activity to be: ❒ I participated in the entire activity and claim 1.75 credits. ❒ I participated in only part of the activity and claim ______ credits. S40 VOL. 8 SUPPL. 1 2006 REVIEWS IN UROLOGY

Side Content